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A B S T R A C T
The ability of tumor necrosis factor (TNF)-a inhibitors to impair pivotal pro-inﬂammatory host defenses
may facilitate the development of disseminated cryptococcosis. Gastrointestinal (GI) tract disease is an
unusual presentation of this yeast infection. We describe a unique case of disseminated cryptococcosis
presenting as colitis that mimicked an exacerbation of Crohn’s disease in a TNF-a inhibitor recipient.
Review of existing literature shows that in immunocompromised patients, GI cryptococcosis invariably
coexists with disseminated cryptococcosis, often lacks prominent GI symptomatology, and is primarily
diagnosed postmortem. In cases with opportunistic infections, discontinuation of TNF-a inhibitors is a
common practice, however rapid rebound of inﬂammatory responses may incur the risk of immune
reconstitution syndrome.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Cryptococcosis is a signiﬁcant opportunistic infection in immu-
nocompromised hosts, particularly in HIV-infected patients or solid
organ transplant (SOT) recipients.1–4 Since the advent of highly
active antiretroviral therapy, the incidence of cryptococcal disease in
HIV-infected patients has signiﬁcantly decreased.5,6 However, the
availability in the current era of an expanded armamentarium of
immunomodulatory therapies suchas tumornecrosis factor (TNF)-a
inhibitors, has led to the emergenceof anewsubset of patients at risk
for developing cryptococcal disease.7,8 Cryptococcus neoformans is
believed to be acquired through inhalation, and disseminates
hematogenously. The most common sites of cryptococcal disease
are the central nervous system (CNS), lungs, and skin followed by
prostate and eye. However, gastrointestinal (GI) involvement due to
cryptococcosis is extremely rare. Indeed, experts believe that there is
little proof that this yeast causes GI disease.9We report herein a case
of disseminated cryptococcosis presenting as colitis in a patientwith
Crohn’s disease receiving inﬂiximab, and review the existing
literature onGI cryptococcosis.We also discuss topicalmanagement
issues regarding cryptococcosis in the contextofTNF-a inhibitoruse.
2. Case report
A 53-year-oldmale with Crohn’s disease and silicosis presented
with a 4-week history of intermittent abdominal pain and* Corresponding author. Tel.: +1 412 360 1688; fax: +1 412 360 6950.
E-mail address: nis5@pitt.edu (N. Singh).
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doi:10.1016/j.ijid.2009.05.019worsening diarrhea. He was originally diagnosed with Crohn’s
disease at the age of 19 and had undergone colonic resection twice
for bowel obstruction. For the past 3 years, he had been receiving
inﬂiximab 5 mg/kg every 8 weeks in addition to azathioprine. The
tuberculin skin test was negative prior to the initiation of
inﬂiximab. The last dose of inﬂiximab was 6 weeks prior to
admission. He had received a 2-week course of oral prednisone
40 mg/day for presumed exacerbation of Crohn’s disease, however
his diarrhea and abdominal pain worsened. He eventually
developed fever, night sweats, and headache. Colonoscopy
revealed a linear ulcer near the terminal ileum, which was not
deemed consistent with an exacerbation of Crohn’s disease. The
Grocott and periodic acid Schiff (PAS) stain of the ileal and colonic
biopsy showed yeast forms with a surrounding clear zone
consistent with cryptococcal colitis. Azathioprine was discontin-
ued and the dose of prednisone was decreased to 20 mg/day. The
patient was referred to our facility for further management.
On examination, the blood pressure was 122/90 mmHg, heart
rate was 108 per min, body temperature was 39.4 8C, and oxygen
saturationwas 97% on roomair. He appeared to be acutely ill. There
was mild tenderness in the lower abdomen. The remainder of the
examination was normal. The white blood cell (WBC) count was
2.4  109/l with 27% band forms. The hemoglobin was 12.4 g/dl
and platelet count was 42  109/l. The creatinine was 1.7 mg/dl. A
liver function test revealed total bilirubin 2.6 mg/dl, alanine
aminotransferase 79 IU/l, aspartate aminotransferase 107 IU/l, and
alkaline phosphatase 232 IU/l. Computed tomography (CT) of the
abdomen and pelvis was unremarkable, however multiple ill-
deﬁned nodules in bilateral lower lungs, suggestive of silicosis or
pulmonary cryptococcosis, were documented. CT of the head wasses. Published by Elsevier Ltd. All rights reserved.
Table 1
Gastrointestinal cryptococcosis in the literature
Study ref. Age/gender Underlying disease Symptoms attributable to
cryptococcosis
GI disease or site Diagnostic method
for GI disease
Disseminated
disease
Treatment Outcome
[19] 25/M CML, chemotherapy - Colonic ulcer Autopsy Yes None Died
[20] 16/M None Diarrhea, abdominal pain,
hematochezia
Colonic mass Laparotomy No Surgery, AmBd + sulfadiazine Cured
[21] 31/M Job’s syndrome Hematemesis Esophageal mass
and ulcer
Endoscopy No AmBd + 5FC for 6 weeks Cured
[22] 29/F Job’s syndrome Draining perirectal abscess Colonic stricture,
perirectal abscess
Laparotomy No Surgery, AmBd for 10 weeks Cured
[23] 47/M AIDS Hematochezia, fever Perirectal abscess,
anal ulcer with a ﬁstula
Proctoscopy Yes AmBd + 5FC, surgery Cured
[24] 48/F CLL, splenectomy,
corticosteroids,
chlorambucil
Abdominal pain, muscle
weakness, dysphagia
Colonic dilatation,
esophagus
Autopsy Yes AmBd + 5FC Died
[25] 63/M Cirrhosis,
splenectomy,
corticosteroids
Fever, chills, malaise Colitis Colonoscopy Yes AmBd + 5FC Died
[18] 31/M AIDS Hemiplegia, seizure Colon Autopsy Yes AmBd + 5FC Died
[18] 31/M AIDS No GI symptomsa Stomach, duodenum Endoscopy Yes AmBd + 5FC Cured
[18] 30/M AIDS Abdominal pain Stomach Autopsy Yes None Died
[17] 38/M AIDS Epigastric pain, odynophagia Gastric and duodenal
nodules, cecum
Endoscopy, autopsy Yes Antifungal therapy Died
[17] 36/M AIDS - Esophagus Autopsy Yes - Died
[17] 53/F Acute leukemia - Esophagus, stomach Autopsy Yes - Died
[17] 24/M Hodgkin’s disease - Esophagus, colon Autopsy Yes - Died
[17] 53/F Malignant lymphoma - Ileum Autopsy Yes - Died
[17] 29/M AIDS - Small intestine Autopsy Yes - Died
[17] 31/F AIDS - Colon Autopsy Yes - Died
[17] 51/M ITP, corticosteroids - Colon Autopsy Yes - Died
[26] 30/M AIDS (CD4 2) Epigastric pain, fever, headache Gastric and duodenal
ulcers
Endoscopy Yes AmBd Died
[27] 37/M AIDS Epigastric pain, fever, headache Duodenum (white
plaque-like lesions)
Endoscopy Yes AmBd Cured
[27] 35/M AIDS Epigastric pain, fatigue Gastric nodules Endoscopy Yes - Died
[27] 44/M AIDS Abdominal pain, fever, headache Gastritis with erosion Endoscopy Yes AmBd Cured
[28] 84/F None Rectal bleeding Colonic polyp Colonoscopy No Noneb Cured
[29] 35/M AIDS (CD4 281) Fever, weight loss Esophageal ulcer Endoscopy Yes LAmB for 2 weeks, then Flu Cured
[30] 48/M Heart transplant,
corticosteroids,
azathioprine,
cyclosporine
Anasarca, skin lesions Chronic duodenitis Endoscopy Yes AmBd + 5FC Improvedc
[31] 50/M None Abdominal pain Jejunal perforation Laparotomy No Flu Died
[32] 39/F AIDS (CD4 306) Abdominal pain, vomiting Ileal stricture Laparotomy Yes AmBd + 5FC for 2 weeks,
then Flu, surgeryd
Cured
[33] 40/M AIDS (CD4 40) Abdominal pain, diarrhea,
dysphagia, fever
Colon (patchy lesions) Sigmoidoscopy Yes AmBd + 5FC Cured
[34] 30/F AIDS (CD4 200) Abdominal pain, vomiting Jejunal perforation Laparotomy No AmBd for 2 weeks, then Flu,
surgery
Cured
[35] 27/F None Melena Colonic mass Colonoscopy No AmBd for 4 weeks, then Flu
for 6 months
Cured
GI, gastrointestinal; CML, chronic myelogenous leukemia; AmBd, amphotericin B; 5FC, ﬂucytosine; CLL, chronic lymphocytic leukemia; ITP, idiopathic thrombocytopenia; LAmB, liposomal amphotericin B; Flu, ﬂuconazole.
a The patient complained of odynophagia due to cytomegalovirus esophagitis.
b The polyp was excised during colonoscopy.
c The patient committed suicide.
d The patient was diagnosed with cryptococcal meningitis 4 weeks prior to the development of abdominal pain. She had received AmBd + 5FC for 2 weeks followed by Flu consolidation therapy.
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Table 2
Characteristics of patients with gastrointestinal cryptococcosis (N = 30)
Characteristic Value
Age (years), median (range) 35.5 (16–84)
Gender, n (%)
Male 21 (70)
Female 9 (30)
Underlying disease, n (%)
HIV 16 (53)
Hematological malignancy 5 (17)
Immunosuppressive agents 5 (17)
Job’s syndrome 2 (7)
Solid organ transplant 1 (3)
Cirrhosis 1 (3)
Splenectomy 2 (7)
None 4 (13)
Site of gastrointestinal involvement, n (%)
Colon 14 (47)
Stomach or duodenum 9 (30)
Esophagus 6 (20)
Small intestine 5 (17)
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bacilli. Cerebrospinal ﬂuid (CSF) analysis revealed an opening
pressure of 210mmH2O,WBC count of 2  106/l (lymphocyte 94%),
red blood cell count of 28  106/l, protein of 46 mg/dl, and glucose
of 41 mg/dl. India ink stain was positive for encapsulated yeasts.
Serum and CSF cryptococcal antigen titers were >1:1024 and
1:512, respectively. Cultures of the blood and CSF yielded C.
neoformans. Disseminated cryptococcal disease in the CNS and
colon that fulﬁlled the criteria of proven cryptococcosis as per
EORTC/MSG criteria was diagnosed.10
Amphotericin B deoxycholate (AmBd) and 5-ﬂucytosine (5FC)
were employed and the dose of prednisone was lowered to 10 mg/
day.AmBdwasswitched to liposomalamphotericinB (LAmB)onday
3 of treatment because of onset of acute renal failure. His headache
and abdominal pain improved by day 4. CSF culture remained
positive on day 9 and eventually became negative on day 15. LAmB
and 5FC were substituted with ﬂuconazole 400 mg/day on day 19.
The patient remained well at current follow-up of 45 days.
3. Methods
We reviewed the existing literature on GI cryptococcosis.
Cases were identiﬁed in PubMed by cross-referencing the
medical subject headings (MeSH) keywords cryptococcosis
and gastrointestinal diseases. The search was restricted to
English or Spanish language articles, however relevant reports
with an English abstract were included. Bibliographies of
original articles were manually reviewed. Only the reports that
met the criteria for proven or probable GI cryptococcosis were
included.10 Hepatobiliary or peritoneal cryptococcosis was not
included in this review.11–14 Disseminated infection was deﬁned
as CNS infection or fungemia or involvement of 2 noncontig-
uous organ sites.15
4. Discussion
Our patient presented with worsening abdominal pain and
diarrhea unresponsive to empirical use of corticosteroids for
presumed exacerbation of Crohn’s disease, which prompted
further evaluation and led to the diagnosis of disseminated
cryptococcosis in the CNS and colon, and presumably in the
lungs. The case is unique because GI manifestations of
cryptococcosis are unusual. Furthermore, only a handful of
cases of cryptococcal disease have been reported in patients
receiving TNF-a inhibitors.
Although disseminated cryptococcal disease may invade any
organ, GI cryptococcosis has rarely been reported.1,4 In a French
nationwide retrospective survey of cryptococcosis, none of the
1057 cases had GI cryptococcosis despite the fact that dissemina-
tion was documented in 16.5% of the patients.16 In contrast, 33%
(8/24) of the patients with disseminated or pulmonary crypto-
coccal disease had evidence of GI involvement in a retrospective
autopsy review.17 Except for the one casewith epigastric painwho
was eventually diagnosed with gastric cryptococcosis, none were
suspected of having GI involvement antemortem.17 In another
autopsy review, 8% (2/23) of the patients with cryptococcal
disease had asymptomatic GI involvement.18 These studies
suggest that GI cryptococcosis may be more prevalent than
previously thought, but is rarely symptomatic and is primarily
diagnosed postmortem.
In our review, a total of 30 cases of GI cryptococcosis were
identiﬁed (Table 1).17–35 Demographic and clinical characteristics
of the patients are outlined in Table 2. Clinical manifestations of GI
cryptococcosis differed notably for immunocompetent compared
with immunocompromised patients. Overall, 88% (23/26) of the
immunocompromised patients had GI cryptococcosis as part ofdisseminated disease as compared to none (0/4) of the immuno-
competent patients (p = 0.001, two-sided Fisher’s exact test). In
immunocompromised patients, three of the 26 cases had localized
GI cryptococcosis that manifested as an esophageal mass,21
perirectal abscess,22 and perforated jejunum.34 The underlying
condition in 2/3 cases with localized cryptococcosis was Job’s
syndrome. The majority of cases of GI cryptococcosis in
immunocompromised hosts were diagnosed either upon evalua-
tion of GI complaints (12 cases) or postmortem (11 cases), however
there were three patients in whom despite the lack of GI
complaints, the diagnosis was established antemortem based on
incidental ﬁndings on CT scan or endoscopy.18,25,29 Two patients
were diagnosed with disseminated cryptococcosis and CT scan
unexpectedly revealed esophageal or colonic wall thickening,
which prompted a biopsy.25,29 The other patient with cryptococcal
meningitis underwent endoscopy for the evaluation of odynopha-
gia and was diagnosed with cytomegalovirus esophagitis. Endo-
scopy also showed yellowish ﬁnely granular mucosa in the
stomach, biopsy of which led to the diagnosis of cryptococcosis.18
These cases suggest that GI involvement in disseminated
cryptococcal disease may be relatively asymptomatic. Overall,
11/15 (73%) of the immunocompromised patients diagnosed with
GI cryptococcosis antemortem improved with antifungal therapy
alone or in combination with surgical resection. Four patients died
of multiple organ failure following suspected bowel perforation
after a colonic biopsy25 or disseminated cryptococcosis.17,26,27
In immunocompetent patients, clinical manifestations of GI
cryptococcosis included colonic mass,20,35 perforated jejunum,31
and colonic polyp.28 All (4/4) had GI symptoms that led to further
investigation, however none were diagnosed with disseminated
cryptococcosis. Three patients recovered completely with anti-
fungal therapy, surgical resection, or their combination. One
patient died of acute respiratory distress syndrome that was not
attributable to cryptococcosis.31
An important issue in patients with life-threatening opportu-
nistic infections is themanagement of immunosuppressive agents.
In a meta-analysis of randomized controlled trials, patients
receiving TNF-a inhibitors were two-fold more likely to develop
an infection compared to those receiving placebo.36 One case of
infection requiring antimicrobial therapy or hospitalization is
estimated to occur for every 59 patients with rheumatoid arthritis
treated with TNF-a inhibitors for 3–12 months.36 Granulomatous
infections were reported to the US Food and Drug Administration
at a rate of 129 and 60 per 100 000 in patients who received
R. Osawa, N. Singh / International Journal of Infectious Diseases 14 (2010) e436–e440 e439inﬂiximab and etanercept, respectively.37,38 Although tuberculosis
is the major infection, invasive fungal disease has been increas-
ingly recognized in patients receiving TNF-a inhibitors.7,8,37,38 In a
recent review, 28 cases of cryptococcal disease were identiﬁed
among a total of 281 cases of invasive fungal disease.8
TNF-a effects a number of critical components of the host
immune system that may account for the propensity of TNF-a
inhibitor recipients to develop cryptococcosis.39 For example, TNF-
a is essential for the formation of granuloma, which prevents
dissemination of the pathogens.40,41 It also recruits inﬂammatory
cells to the site of infection and stimulates the production of
interferon-g, leading to phagocytosis and killing of intracellular
organisms.39,42,43 Moreover, TNF-a plays a major role in the
development of T cell-mediated immunity to C. neoformans. In a
mice model of pulmonary cryptococcosis, administration of TNF-a
inhibitor at the time of cryptococcal inoculation led to impairment
in the induction of Cryptococcus-speciﬁc delayed type hypersensi-
tivity, failure in eradication of infection in the lungs, and increased
risk of dissemination to spleen and brain.44
Considering these effects, discontinuation of TNF-a inhibitors
upon diagnosis of opportunistic infection appears to be intuitively
rational. However, accumulating evidence shows that abrupt
reduction of potent immunosuppressive therapy may lead to
exacerbation of inﬂammatory response and potentially the
development of immune reconstitution syndrome (IRS). IRS
comprises localized and systemic inﬂammatory reactions trig-
gered by rapid restoration of host immunity during an opportu-
nistic infection and may cause serious consequences, including
fatality.45,46 Although IRS has been observed mainly in HIV-
infected patients and SOT recipients,47,48 an abrupt shift towards a
pro-inﬂammatory response upon discontinuation of TNF-a
inhibitors may also lead to IRS.49,50
While the optimal management of immunosuppressive
therapy in TNF-a inhibitor recipients still remains to be
elucidated, the prevailing wisdom is to discontinue TNF-a
inhibitors in cases with serious infections.51 Monitoring the
development of IRS as well as the activity of underlying
inﬂammatory disease upon discontinuation of TNF-a inhibitors
is crucial.49,50 Clinical manifestations of TNF-a inhibitor-asso-
ciated IRS in patients with tuberculosis included primarily
lymphadenitis and exacerbation of pulmonary inﬁltrates.49,50
Although Cryptococcus-associated IRS has not been reported in
patients receiving TNF-a inhibitors to our knowledge, aseptic
meningitis and lymphadenitis are common in HIV-infected
patients or SOT recipients with cryptococcal IRS.47,48 Most cases
of opportunistic infection-associated IRS resolve spontaneously.
However, corticosteroids have been employed in patients with
serious or life-threatening disease. Paradoxically, the inhibitors of
pro-inﬂammatory responses, namely TNF-a inhibitors, could also
be effective for the treatment of IRS. Indeed, inﬂiximab was
successfully employed to inhibit pathogenic inﬂammatory
response due to refractory IRS in a patient with neurotuberculosis
after initiation of anti-tuberculous therapy.52 These data illustrate
the importance of achieving a balance in immune responses that
enhance protective host immunity while curbing unfettered
inﬂammation in IRS.
In summary, our case and review demonstrate that GI
cryptococcosis appears to occur locally in immunocompetent
patients with excellent outcome; however it seems to coexist with
disseminated disease in immunocompromised patients. Patients
receiving TNF-a inhibitors are at increased risk for developing
granulomatous opportunistic infections, including cryptococcosis
that may have atypical or diverse manifestations. Finally, under-
standing the precise effects of TNF-a inhibitors on the immune
system can yield further insights into optimizing the management
of these opportunistic infections.Acknowledgements
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